证券日报网讯 12月10日晚间，德源药业发布公告称，2025年12月9日，江苏德源药业股份有限公司按照 化学药品3类申报的别嘌醇片收到国家药品监督管理局（NMPA）核准签发的药品注册证书，且视同通 过一致性评价。 （文章来源：证券日报） ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 19, with Hainan Haiyao leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shanhe Pharmaceutical (300452) with a closing price of 15.07, up 9.04% and a trading volume of 390,200 shares, totaling 586 million yuan [1] - ST Suhao (600200) closed at 1.02, up 5.15% with a trading volume of 429,200 shares [1] - ST Jingfeng (000908) closed at 66.8, up 5.02% with a trading volume of 354,800 shares [1] - Major decliners included: - Muan Nanhai (000566) with a closing price of 7.20, down 10.00% and a trading volume of 2,192,500 shares, totaling 1.625 billion yuan [2] - Sitaili (603520) closed at 10.66, down 6.74% with a trading volume of 315,600 shares [2] - Yatai Pharmaceutical (002370) closed at 7.79, down 6.59% with a trading volume of 1,044,700 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.278 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.139 billion yuan [2] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (300255) with a net inflow of 71.90 million yuan, accounting for 6.20% of total inflow [3] - Xingqi Eye Medicine (300573) with a net inflow of 70.33 million yuan, representing 12.29% [3] - Shanhe Pharmaceutical (300452) with a net inflow of 68.13 million yuan, making up 11.62% [3]

Group 1 - The event "Investor Zero Distance" focused on the company Deyuan Pharmaceutical, part of the North Exchange 50 index, highlighting its innovative growth in the pharmaceutical industry [2][7] - Over 40 institutional representatives and investors participated in the event, engaging with company executives to understand the company's operations and market potential [2][6] - Deyuan Pharmaceutical specializes in the research, production, and sales of chronic disease treatment drugs, particularly in the endocrine therapy sector, and is expanding its product pipeline in related fields [4][6] Group 2 - The company's chairman and board secretary provided insights into the current business operations, strategic direction, and core technologies during face-to-face discussions with investors [6] - Industry experts discussed the North Exchange market, the North Exchange 50 index fund, and the long-term investment value of the A-share pharmaceutical sector during a subsequent seminar [6] - The event aimed to enhance communication between investors and listed companies, fostering a better understanding of company fundamentals and promoting rational investment culture [7]

Group 1 - The core viewpoint of the articles highlights a significant surge in the innovative drug sector within the A-share market, particularly on October 31, where several stocks, including Shuyat and Sanofi, hit the 20% daily limit increase [1] - The A-share market experienced fluctuations, with the ChiNext index dropping over 2%, and the total trading volume in the Shanghai and Shenzhen markets reaching 2.32 trillion yuan, a decrease of 103.9 billion yuan compared to the previous trading day [1] - The introduction of the "Commercial Insurance Innovative Drug Directory" mechanism during the national medical insurance negotiations is expected to benefit innovative drugs that are highly innovative and clinically valuable but are not yet included in the basic directory [1] Group 2 - According to Guosen Securities, the Chinese innovative drug industry is showing a long-term positive development trend, particularly evident in the explosive growth of BD transactions in recent years [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners overseas and subsequent global clinical data readings enhancing the certainty of commercialization in the global market [2] - The long-term logic of investing in innovative drugs is favored, with a focus on stocks that are showing signs of bottom reversal [2]

Core Viewpoint - The innovation drug sector is experiencing significant market activity, driven by supportive government policies aimed at promoting the development of innovative drugs and medical devices in China [1] Group 1: Market Performance - Companies such as Sanofi, Sihuan Pharmaceutical, and Zai Lab have seen stock price increases of 20% or more, indicating strong investor interest in the innovation drug sector [1] - Other companies like Maiwei Biotech and Deyuan Pharmaceutical have also reported stock price increases exceeding 10% [1] Group 2: Policy Support - The "14th Five-Year Plan" suggests support for the development of innovative drugs and medical devices, with a focus on four key areas: R&D support, commercial health insurance innovation drug catalog, optimization of drug pricing mechanisms, and support for the application of innovative drugs and devices [1] - The Chinese government has reiterated its commitment to supporting the innovation drug sector starting in 2025, indicating a long-term strategy for growth [1] Group 3: Industry Challenges and Solutions - According to CITIC Securities, the current bottlenecks in the domestic innovation drug development are primarily in the payment and application sectors [1] - The development of commercial health insurance is deemed essential, with the establishment of a commercial insurance catalog playing a guiding role in market pricing for innovative drugs [1] - Strategies such as DRG/DIP exclusion payment, accelerated hospital promotion, and diversified payment methods are identified as key measures for the domestic development of innovative drugs [1]

Core Points - The Shanghai Composite Index closed at 3961.62 points, above the six-month moving average, with a decline of 0.63% [1] - The total trading volume of A-shares reached 157.92 billion yuan [1] - A total of 259 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3961.62 points, indicating a slight decline of 0.63% [1] - The total trading volume for A-shares today is reported at 157.91 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 259 A-shares have broken through the six-month moving average, with the highest deviation rates observed in stocks such as: - Yatong Precision Engineering (8.20%) - Excellent New Energy (7.57%) - Deyuan Pharmaceutical (7.38%) [1] - Other stocks with smaller deviation rates include: - New Hope - Shanghai Phoenix - Angli Education, which have just crossed the six-month line [1] Notable Stocks and Their Metrics - Top stocks with significant price changes and their metrics include: - Yatong Precision Engineering: +9.76%, turnover rate 31.45%, six-month line 23.27 yuan, latest price 25.18 yuan, deviation rate 8.20% [1] - Excellent New Energy: +9.90%, turnover rate 2.44%, six-month line 45.62 yuan, latest price 49.07 yuan, deviation rate 7.57% [1] - Deyuan Pharmaceutical: +11.83%, turnover rate 8.02%, six-month line 38.03 yuan, latest price 40.84 yuan, deviation rate 7.38% [1]

国浩律师（南京）事务所 关 于 江苏德源药业股份有限公司 2025 年第一次临时股东会 之 法律意见书 国浩律师(南京)事务所 法律意见书 国浩律师（南京）事务所 南京市汉中门大街 309 号 B 座 5/7/8 层 邮编：210036 5,7,8th Floor, Block B, 309 Hanzhongmen Street, Nanjing 210036, China 电话/Tel: +86 25 8966 0900 传真/Fax: +86 25 8966 0966 网址/Website: http://www.grandall.com.cn 2025 年 9 月 | 一、 | 关于本次临时股东会的召集、召开程序 2 | | --- | --- | | 二、 | 关于本次临时股东会出席人员的资格和召集人资格 3 | | 三、 | 关于本次临时股东会的表决程序及表决结果 4 | | 四、 | 结论意见 7 | | | 签署页 9 | 关于江苏德源药业股份有限公司 2025年第一次临时股东会之法律意见书 致：江苏德源药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国 ...

证券代码：832735 证券简称：德源药业 公告编号：2025-092 江苏德源药业股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 一、会议召开和出席情况 4.会议召集人：董事会 5.会议主持人：董事长陈学民 6.召开情况合法合规的说明： 本次会议的召集、召开符合《中华人民共和国公司法》《北京证券交易所股票上 市规则》等有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规 定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 15 人，持有表决权的股份总数 49,430,964 股，占公司有表决权股份总数的 42.1349%。 其中参加现场股东会的股东共 9 人，持有表决权的股份总数 37,629,104 股，占 公司有表决权股份总数的 32.0750 %。 （一）会议召开情况 1.会议召开时间：2025 年 9 月 25 日 2.会议召开地点：江苏省连云港经济技术开发区长江路 29 号公司三楼会议室 3.会议召开方式：现场投票和网络投 ...

江苏德源药业股份有限公司章程 江苏德源药业股份有限公司 章程 （2025 年 9 月） | 第一章 | 总 则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第四章 | 股东和股东会 6 | | 第一节 | 股东 6 | | 第二节 | 控股股东和实际控制人 9 | | 第三节 | 股东会的一般规定 10 | | 第四节 | 股东会的召集 17 | | 第五节 | 股东会的提案与通知 18 | | 第六节 | 股东会的召开 20 | | 第七节 | 股东会的表决和决议 22 | | 第五章 | 董事会 27 | | 第一节 | 董事 27 | | 第二节 | 董事会 31 | | 第三节 | 独立董事 36 | | 第四节 | 董事会专门委员会 38 | | 第六章 | 高级管理人员 40 | | 第七章 | 财务会计制度、利润分配和审计 42 | | 第一节 | 财务会计制度 42 | | 第二节 | 内部审计 46 | | 第三节 | ...

Investment Rating - The report indicates a strong rebound in the North Exchange, with a focus on the technology growth sector, particularly semiconductors and robotics, which are seen as core investment themes [4][9]. Core Insights - The North Exchange A-shares trading volume reached 20.69 billion yuan on September 24, a decrease of 3.72 billion yuan from the previous trading day, while the North Exchange 50 Index closed at 1578.92, up 2.03% [2][9]. - The North Exchange specialized and innovative index closed at 2762.51, increasing by 2.66% [2][9]. - Among the 276 companies listed on the North Exchange, 236 saw their stock prices rise, 2 remained flat, and 38 experienced declines [2][16]. Summary by Sections Market Review - On September 24, the North Exchange A-shares trading volume was 20.69 billion yuan, down from the previous day by 3.72 billion yuan [2][9]. - The North Exchange 50 Index increased by 2.03%, with a PE_TTM of 74.04 [2][9]. - The specialized and innovative index rose by 2.66% [2][9]. - The top five gainers included Henghe Co. (30.0%), Meizhigao (10.6%), Kaide Quartz (9.9%), Tiangang Co. (8.9%), and Yuanhang Precision (8.3%) [2][16]. - The top five decliners were Anhui Phoenix (-4.4%), Hongzhi Technology (-3.6%), Rongyi Precision (-3.0%), Wantong Hydraulic (-2.9%), and Tianma New Materials (-2.7%) [2][16]. Important News - Eight departments issued guidelines to promote digital consumption, proposing 14 tasks across four areas to enhance the digital consumption ecosystem [3][19]. - The "Vehicle-Road-Cloud Integration" pilot city construction is accelerating, with various cities, including Beijing and Haikou, advancing related projects [3][20]. Key Company Announcements - Kexin New Materials announced the acquisition of a utility model patent for a fixed device for transporting new energy crucibles [3][21]. - Xici Technology plans to invest up to 160 million yuan of idle funds in safe financial products [3][21].